Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

ABSTRACT: In this study, the investigators assessed the effect of avastin in combination with chemotherapy in the treatment of RAS mutant-type, unresectable colorectal liver-limited metastases

DISEASE(S): Neoplasm Metastasis,Colorectal Neoplasms

PROVIDER: 2153900 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients

Project description:establishment and validation of the prediction model of avastin plus chemotherapy as first line treatment in simultaneous ras mutant unresectable CRLM patients

| 2349750 | ecrin-mdr-crc

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Project description:Colorectal cancer patients with initially unresectable liver-only metastases may be cured after downsizing of metastases by conversion therapy. However, the optimal regimen of conversion therapy for RAS mutant patients has not been defined. In this study colorectal cancer patients with initially unresectable liver-only metastases, as prospectively confirmed by a local multidisciplinary team (MDT) according to predefined criteria, will be tested for RAS and BRAF tumor mutation status. Patients with RAS mutant and BRAF wild type will be randomised between modified FOLFOXIRI (mFOLFOXIRI) plus bevacizumab and modified FOLFOX6 (mFOLFOX6) plus bevacizumab. Patient imaging will be reviewed for resectability by MDT, consisting of at least one radiologist and three liver surgeons every assessment. MDT review will be performed prior to randomization as well as during treatment, as described in the protocol.

| 2369422 | ecrin-mdr-crc

Paired Human Glioblastoma Pre and Post Avastin Treatment

Project description:Paired samples of resected tumor from glioblastoma patients: Pre and post Avastin-treatment samples for each patient in the cohort.

2012-09-30 | E-MEXP-3296 | biostudies-arrayexpress

S. cerevisiae mutant with a constitutively activated Ras/cAMP pathway

Project description:Comparison of the transcriptomes of Saccharomyces cerevisiae wild type FY23 and a PDE2 deletion mutant DJ28. Keywords = PDE2 Keywords = Ras/cAMP pathway Keywords: other

2003-08-19 | GSE600 | GEO

Injury prevents Ras mutant cell expansion in mosaic skin

Project description:Injury prevents Ras mutant cell expansion in mosaic skin

| PRJNA802561 | ENA

Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC

Project description:Resistance to inactive state-selective RASG12C inhibitors frequently entails accumulation of RASGTP, rendering effective inhibition of active RAS potentially desirable. Here, we evaluated the anti-tumor activity of the RAS(ON) multi-selective tri-complex inhibitor RMC-7977 and dissected mechanisms of response and tolerance in KRASG12C-mutant NSCLC. Broad-spectrum, reversible RASGTP inhibition with or without concurrent covalent targeting of active RASG12C yielded superior and differentiated antitumor activity across diverse co-mutational KRASG12C-mutant NSCLC mouse models of primary or acquired RASG12C(ON) or (OFF) inhibitor resistance. Interrogation of time-resolved single cell transcriptional responses established an in vivo atlas of multi-modal acute and chronic RAS pathway inhibition in the NSCLC ecosystem and uncovered a regenerative mucinous transcriptional program that supports long-term tumor cell persistence. In patients with advanced KRASG12C-mutant NSCLC, the presence of mucinous histological features portended poor response to sotorasib or adagrasib. Our results have potential implications for personalized medicine and the development of rational RAS inhibitor-anchored therapeutic strategies.

2024-06-27 | GSE270541 | GEO

Keap1 deletion-based Nrf2 activation accelerates mutant K-ras/p53-driven cholangiocarcinoma

Project description:Addition of liver-specific Keap1 deletion to mice harboring mutant K-ras and p53 accelerated cholangiocarcinoma formation, with hallmarks of Nrf2 activation.

2021-09-27 | GSE138101 | GEO

Gene expression levels in colon cancer cells with mutant K-ras under hypoxic conditions

Project description:The goal of this study was to identify those genes that were differentially expressed in colon cancer cells with mutant K-ras under hypoxic conditions DKS-5 (K-ras mutant) and DKO-3 (K-ras wild-type) were cultured in normoxic (21% O2) and 12-hour hypoxic (1% O2) conditions. This was repeated for a total of 2 samples per condition.

2012-02-21 | E-GEOD-35973 | biostudies-arrayexpress

Epigenetic Reprogramming of mutant RAS-driven Rhabdomyosarcoma via MEK Inhibition

Project description:Epigenetic Reprogramming of mutant RAS-driven Rhabdomyosarcoma via MEK Inhibition

| PRJNA336377 | ENA

NSCLC metastasis: K-ras/p53 mutant and syngeneic mouse models

Project description:NSCLC metastasis: K-ras/p53 mutant and syngeneic mouse models

| PRJNA111451 | ENA